Kucukdiler, Ayse Hilal ErogluYavasoglu, IrfanSelim, CemMutlu, Cansu AtmacaKarakus, AbdullahKoyuncu, Mahmut BakirBilgir, Oktay2024-04-242024-04-2420212213-0489https://doi.org/10.1016/j.lrr.2021.100280https://hdl.handle.net/11468/15794We retrospectively evaluated the use of gemtuzumab ozogamicin (GO) in relapsed refractory (R/R) acute myeloid leukemia (AML) patients. Twenty-one CD33 positive R/R AML patients who received GO as a single agent in 4 hematology centers were included in this study. The median age was 59, and the median ECOG performance score was 2. According to cytogenetic analysis, 1 patient had favorable risk, 12 patients with in-termediate, and 8 patients with adverse risk. The overall response rate was 52.3%. Partial response was achieved in 3 of 8 patients with adverse risk. 33.3% of patients developed grade 3 anemia. Grade 4 neutropenia and thrombocytopenia were observed in 80% of the patients. One of the patients died due to sinusoidal obstruction syndrome / veno-occlusive disease (SOS / VOD) due to GO side effects. GO may be considered as a good option for salvage therapy in R/R AML patients.eninfo:eu-repo/semantics/openAccessGemtuzumab OzogamicinAcute Myeloid LeukemiaSalvage TreatmentArticle16WOS:0010511527000052-s2.0-851193000863484933710.1016/j.lrr.2021.100280Q3N/A